Children's Cancer and Leukaemia Group   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Leicester United Kingdom (1977)

Organization Overview

First Clinical Trial
1989
NCT00276718
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Children's Cancer and Leukaemia Group

Active Ingredients

Drugs in Phase 3 Trials (34)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

asparaginase (elspar) (2 trials)

autologous hematopoietic stem cells (8 trials)

bleomycin (blenoxane) (4 trials)

bone autograft (3 trials)

busulfan (Myleran) (4 trials)

carboplatin (paraplatin) (17 trials)

cisplatin (platinol) (15 trials)

cyclophosphamide (cytoxan) (18 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (3 trials)

dactinomycin (cosmegen) (5 trials)

daunorubicin (cerubidine) (1 trial)

doxorubicin (Doxil) (16 trials)

etoposide (vepesid) (21 trials)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (7 trials)

leucovorin (2 trials)

melphalan (alkeran) (6 trials)

mercaptopurine (purinethol) (1 trial)

mitoxantrone (novantrone) (1 trial)

mycophenolate (CellCept) (1 trial)

naltrexone (revia) (7 trials)

pegaspargase (oncaspar) (1 trial)

prednisone (meticorten) (5 trials)

sargramostim (leukine) (6 trials)

sodium thiosulfate (1 trial)

tioguanine (Lanvis) (1 trial)

topotecan (hycamtin) (3 trials)

urea (4 trials)

vinblastine (velban) (4 trials)

vincristine (oncovin) (23 trials)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (13)

125-iodine (1 trial)

chlorambucil (Leukeran) (3 trials)

dacarbazine (dtic-dome) (2 trials)

epirubicin (ellence) (1 trial)

irinotecan (Camptosar) (2 trials)

lomustine (2 trials)

metaiodobenzylguanidine (1 trial)

motexafin gadolinium (1 trial)

procarbazine (matulane) (3 trials)

tamoxifen (nolvadex) (1 trial)

temozolomide (temodar) (3 trials)

thalidomide (Thalomid) (1 trial)

thiotepa (2 trials)

Drugs in Phase 1 Trials (1)

erlotinib (tarceva) (1 trial)

Drugs in Other Trials (4)

granulocytes (1 trial)

isotretinoin (Accutane) (1 trial)

povidone (1 trial)

teicoplanin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 1)

Central Nervous System Neoplasms (Phase 3)

Ependymoma (Phase 2)

Glioma (Phase 2)

Hepatoblastoma (Phase 3)

Histiocytoma (Phase 3)

Histiocytoma, Benign Fibrous (Phase 3)

Histiocytoma, Malignant Fibrous (Phase 3)

Intestinal Neoplasms (Phase 2)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Liver Neoplasms (Phase 3)

Lymphohistiocytosis, Hemophagocytic (Phase 3)

Lymphoma (Phase 3)

Medulloblastoma (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Nervous System Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Sarcoma, Clear Cell (Phase 2)

Sarcoma, Ewing (Phase 2)

Wilms Tumor (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 49
  • # of Trial APIs: 52